Metastatic melanoma is challenging to manage. Although targeted-and immune therapies
have extended survival, most patients experience therapy resistance. The adaptability of …

Simple Summary Patients with advanced melanoma are often treated with v-raf murine
sarcoma viral oncogene homolog B1 (BRAF) inhibitors. Although these agents prolong life …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous
melanoma have been significantly revised over the past few years in response to emerging …

Abstract Ulixertinib (BVD-523) is an ERK1/2 kinase inhibitor with potent preclinical activity in
BRAF-and RAS-mutant cell lines. In this multicenter phase I trial (NCT01781429), 135 …

Highlights•A melanoma consensus conference, organised by the ESMO Guidelines
Committee, was attended by 32 experts from 14 countries•The experts compiled …

Background Colorectal cancer (CRC) has been shown to acquire RAS and EGFR
ectodomain mutations as mechanisms of resistance to epidermal growth factor receptor …

Preclinical modeling suggests that intermittent BRAF inhibitor therapy may delay acquired
resistance when blocking oncogenic BRAF V600 in melanoma,. We conducted S1320, a …

The immunotherapy is currently changing the landscape of oncology. Nowadays the
standard of care in metastatic or unresectable melanoma patients include …

Observations from cultured cells,,, animal models and patients,, raise the possibility that the
dependency of tumours on the therapeutic drugs to which they have acquired resistance …

Background Melanoma lacks validated blood-based biomarkers for monitoring and
predicting treatment efficacy. Cell-free circulating tumour DNA (ctDNA) is a promising …